Cases were defined as women with a diagnosis of invasive breast cancer listed on the NSW Cancer Registry during the study period; 1 July 2004 to 31st December 2008. Codes used to identify cases were International Classification of Diseases version 10 with Australian modifications (ICD-10-AM) C...
81432 Hereditary breast cancer-hyphenrelated disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer); genomic sequence analysis panel, must include sequencing of at least 10 genes, always including BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, PALB2, PTEN, STK1...
Fiberoptic ductoscopy (e.g., microendoscopic intraductal mammary visualization) with the Acueity System for the detection, diagnosis and treatment of breast cancer, is currently being used in research and clinical trial collaborations with a number of academic facilities, including the Cleveland Clinic...
The COVID-19 pandemic significantly impacted breast cancer (BC) surgeries. Most studies showing reduced BC surgical volumes during the pandemic are from si
Case-patient participants were women aged 20–49 years who were diagnosed with a first primary invasive breast cancer (ICD-O codes: C50.0–C50.9) between February 1998 and May 2003 (n = 1794; 1585 white and 209 African-American women). Control participants were women ages 20–49 years...
‘invasive’ describes the cancer’s main feature of spreading to other surrounding breast tissues. The condition starts at the milk ducts, which carries the milk from the lobules to the nipples, and then breaks the wall of the milk tubes and invade the other breast’s tissues. The ICD ...
All in situ or invasive breast cancer derives from terminal tubulobular units; when the tumor is present only in the ducts or lobules in situ, it is called ductal carcinoma in situ (DCIS)/lobular carcinoma in situ (LCIS). The biggest risk factors are age, mutations in breast cancer genes...
DCIS, ductal carcinoma in situ; TNBC, triple-negative breast cancer; AEs, adverse events; SoC, standard of care; ORR, objective response rate; CNS, central nervous system; PFS, progression-free survival; DFS, disease-free survival; pCR, pathologic complete response; IV, intravenous; LNs, lymph...
MarginProbe can be used during lumpectomy for both DCIS and invasive breast cancer. Coble and Reid (2017) noted that following lumpectomy, full cavity shaving approach is used to reduce positive margin rates, among other issues previously studied by others, at an expense of increase in tissue ...
Dysregulated Notch signalling contributes to breast cancer development and progression, but validated tools to measure the level of Notch signalling in breast cancer subtypes and in response to systemic therapy are largely lacking. A transcriptomic signa